Meeting
2020 ASCO Virtual Scientific Program
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
Authors
Filippo de Marinis
Istituto Europeo di Oncologia IRCCS, Milan, Italy
Filippo de Marinis , Giuseppe Giaccone , Roy S. Herbst , Cristina-Marinela Oprean , Aleksandra Szczesna , Ioannis Boukovinas , Lucia Bonomi , Young-Chul Kim , Yvonne J. Summers , Takayasu Kurata , Kimberly Mayumi Komatsubara , Megan Chen , Yu Deng , Hiroshi Kuriki , Simonetta Mocci , See Phan , Jacek Jassem , David R. Spigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02409342
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9594)
DOI
10.1200/JCO.2020.38.15_suppl.9594
Abstract #
9594
Poster Bd #
360
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2018 ASCO Annual Meeting
Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).
First Author: Martin Reck
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
First Author: Martin Reck
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu